Article
Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes defined by international consensus classification.
Blood cancer journal - 9 Aug 2023
Lee Wan-Hsuan, Tsai Ming-Tao, Tsai Xavier Cheng-Hong, Tien Feng-Ming, Lo Min-Yen, Tseng Mei-Hsuan, Kuo Yuan-Yeh, Liu Ming-Chih, Yang Yi-Tsung, Chen Jui-Che, Tang Jih-Luh, Sun Hsun-I, Chuang Yi-Kuang, Lin Liang-In, Chou Wen-Chien, Lin Chien-Chin, Hou Hsin-An, Tien Hwei-Fang
Abstract excerpt
Myelodysplastic syndromes (MDS) have varied prognoses and require a risk-adapted treatment strategy for treatment optimization. Recently, a molecular prognostic model (Molecular International Prognostic Scoring System [IPSS-M]) that combines clinical parameters, cytogenetic abnormalities, and mutation topography was proposed. This study validated the IPSS-M in 649 patients with primary MDS (based on the 2022...
Topics
- Humans
- Prognosis
- Consensus
- Myelodysplastic Syndromes
- Hematopoietic Stem Cell Transplantation
- Mutation